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Aafke Meerveld-Eggink,1 Ankie M. T. van der Velden,2 Gert J. Ossenkoppele,2
Arjan A. van de Loosdrecht,2 Douwe H. Biesma,3 Ger T. Rijkers4After allogeneic stem cell transplantation with reduced-intensity conditioning regimens (allo-RIST) patients
are susceptible to bacterial and viral infections for a period that may last several years. The efficacy of the
recommended vaccination schedules, in terms of induction of a protective antibody response, is unknown.
In this study, the reconstitution of humoral immunity after allo-RIST is determined by measuring the
vaccination-induced antibody response against Streptococcus pneumoniae, Haemophilus influenzae type
b (Hib), and tetanus toxoid (TT) 1 year posttransplantation. Patients who underwent allo-RISTwere vacci-
nated according to a schedule starting at 12 months following transplantation with conjugated vaccines
against S. pneumoniae, Hib, and TT. Of twenty-six patients both pre- and postvaccination sera were available.
Patients were required to be off immunosuppression at the time of vaccination, and, therefore, 9 of the 26
patients did not start vaccination at 12 months post-stem cell transplantation but rather at a median range of
15 (12-36 months) posttransplantation. Except for pneumococcal serotype 6B, more than 73% of the pa-
tients developed antibody levels $0.35 mg/mL for all pneumococcal serotypes included in the vaccine. For
Hib and TT, protective antibody levels were found in 77% and 96% of the patients, respectively. Vaccination
of patients at a median of 15 months post-allo-RIST leads to significant rise in concentrations of pneumococ-
cal, Hib, and TT antibodies in the majority of patients.
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Nonmyeloablative (NMA) allogeneic stem cell
transplantation (or allogeneic stem cell transplantation
with reduced-intensity conditioning regiments [allo-
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6/j.bbmt.2009.07.020of hematologic malignancies. After allo-RIST,
immunosuppressive therapy is required to prevent
severe graft-versus-host disease (GVHD). Because of
this immunosuppressive therapy, thepretransplant che-
motherapy, and the underlying hematologic disease,
patients are susceptible to bacterial and viral
infections for a period that may last up to several years
[1]. Defects in B cell function can last for 12 to 24
months, causing a significant impairment of the
humoral immune system of the host and thereby in-
creasing the susceptibility to infections after transplan-
tation [2]. The humoral immunodeficiency involves
defects in the response to T cell-independent antigens,
including the capsular polysaccharides of Streptococcus
pneumoniae and Haemophilus influenzae type b (Hib), as
well as T cell-dependent protein antigens [2,3]. There-
fore, immunization against these pathogens is recom-
mended by the Centers for Disease Control (CDC)
and the InfectiousDiseasesWorking Party of theEuro-
pean Group for Blood and Marrow Transplantation
(EBMT) [1,4].
Despite the recommendations that have been
implemented widely, limited information is available1523
1524 Biol Blood Marrow Transplant 15:1523-1530, 2009A. Meerveld-Eggink et al.on (the kinetics of) the functional reconstitution of the
cellular and humoral immune system following allo-
RIST. Although there is consensus on the need for
a vaccination program, the efficacy of the recommen-
ded vaccination schedules, in terms of induction of
a protective antibody response, is unknown in the
NMA setting [1]. In this study, the reconstitution of
humoral immunity after allo-RIST is determined by
measuring the antibody response to vaccination against
S. pneumoniae, Hib, and tetanus toxoid (TT) 1 year
posttransplantation.MATERIALS AND METHODS
Patients
From May 2005 until January 2008, patients who
entered the standard vaccination protocol (see the fol-
lowing section) of the Vrije Universiteit (VU) Univer-
sity Medical Center after allo-RIST were included. All
patients gave informed consent. In case of recurrence
of malignant disease that required chemotherapy, pa-
tients were not vaccinated.
Stem Cell Transplantation
All patients received a NMA stem cell transplanta-
tion (SCT); the conditioning regimen consisted of flu-
darabine (Flu; 25 mg/m2 i.v. for 5 days) and
cyclophosphamide (Cy; 500 mg/m2 i.v. for 5 days),
Flu (30 mg/m2 for 3 days) and total body irradiation
(TBI, 2 Gy once) or TBI alone (2 Gy once). GVHD
prophylaxis consisted of mycophenolate mofetil
(MMF) and cyclosporine (CsA) until 3 months post-
transplantation. Thereafter, MMF was stopped in 2
weeks. The CsA was tapered approximately 25%
a week if GVHD had not developed. In case of
GVHD, an alternative scheme of an 8% decrease
a week was used.
Vaccination protocol
The standard vaccination procedure after alloge-
neic SCT starts 1 year after transplantation and con-
sists of 5 vaccination moments with vaccines against
Haemophilus influenzae type b (Act-Hib, Sanofi
Pasteur MSD, Brussels, Belgium), Streptococcus pneu-
moniae (PrevnarWyeth Lederle Vaccines S.A., Lou-
vain-la-Neuve, Belgium and Pneumovax-23, Sanofi
Pasteur MSD, Brussels, Belgium), diphtheria, tetanus
and poliomyelitis (DTP, Nederlands Vaccin Instituut
(NVI), Bilthoven, The Netherlands), and Neisseria
meningitidis serogroup C (Meningitec, Wyeth Phar-
maceuticals B.V., Hoofddorp, the Netherlands) [1,4].
The schedule for this vaccination procedure is given
in Table 1. Blood samples were drawn 1 year after
SCT, that is, prior to the first vaccination, and 3 weeks
after the second vaccination with DTP.Antibody Determinations
Serum samples were collected and stored at220C
until use.Regularly scheduled laboratory investigations
included complete blood count with leukocyte differ-
entiation and chimerism determination. Chimerism
was determined on days 128, 156, 184, 1182, and
1364 after SCT and thereafter every year for 5 years
by means of short tandem repeat (STR) assay. Full
chimerism is defined as .95% of donor origin. T cell
or B cell chimerism were not examined separately.
Antibody titers against Hib and TT were deter-
mined by ELISA as described previously [5-7]. Briefly,
microtiter plates coated with Hib or TT were incu-
bated with serial dilutions of patient sera. Antibody
levels were determined with goat antihuman IgG con-
jugated to alkaline phosphatase, and developed with
p-nitrophenyl phosphate. Data are reported in terms
of proportions of patients who showed response
(defined as a $4-fold increase in antibody titer) and
who attained protective antibody titers. ForHib, an an-
tibody concentration of $1.0 mg/mL is considered to
correlate with long-term protection [8,9]. For tetanus,
antibody concentrations of 0.1 IU/mL are correlated
with long-term protection [10-12].
Antibody levels to 8 pneumococcal serotypes (3, 4,
6B, 9V, 14, 18C, 19F, and 23F) and cell wall polysac-
charide (CWPS) were determined simultaneously
with fluorescent bead-based assay (Luminex). Patient
sera were preabsorbed with pneumococcal serotype
22F to remove CWPS2 [13,14]. Patient sera diluted
1:100 or 1:1000 were incubated with the mixture of
polysaccharide-coated beads. Goat antihuman IgG
conjugated to phycoerythrin was added and samples
were measured on a Bio-plex 100 system (Bio-Rad,
Hercules, CA). The pneumococcal reference serum
89SF was kindly provided by Dr. C.E. Frash, Division
of Bacterial Products, Center for Biologics Evaluation
and Research, Rockville, MD.
The chosen antipneumococcal antibody threshold
for protection against invasive disease was $0.35 mg
IgG/mL, in accordance with recommendations by
the World Health Organisation (WHO) [15]. How-
ever, for immunocompromised patients, and for inva-
sive pneumococcal infections, this threshold is often
not considered to be protective. Therefore, we also
calculated response rates using a higher threshold of
$1.0 mg IgG/mL.
All antibody titers were log-transformed and
geometric mean titers (GMT) were calculated.Statistical Analysis
Comparisons of GMTbefore and after vaccination
(paired samples) were performed using the Wilcoxon
signed rank test. A p-value of#.05 was considered sta-
tistically significant. For independent samples, the
Mann-Whitney U-test was used.
Table 1. Vaccination Protocol after Allogeneic Stem Cell Transplantation
Time Since Transplantation 1 Year +2 Weeks +8 Weeks +12 Weeks +26 Weeks
Vaccines DTP, Hib PCV DTP, PCV, Men-C DTP, Hib PPV23, Hib
DTP indicates diphtheria, tetanus and poliomyelitis vaccine; DTP, Netherlands Vaccine Institute (NVI), Bilthoven, The Netherlands; Hib, Haemophilus
influenzae type b vaccine; Act-Hib, Sanofi Pasteur MSD, Brussels, Belgium; PCV, pneumococcal 7-valent conjugate vaccine; Prevnar, Wyeth Lederle
Vaccines S.A., Louvain-la-Neuve, Belgium; Men-C,Neisseria meningitidis serogroup C vaccine; Meningitec, Wyeth Pharmaceuticals B.V., Hoofddorp, The
Netherlands; PPV23, pneumococcal 23-valent polysaccharide vaccine; Pneumovax-23, Sanofi Pasteur MSD, Brussels, Belgium.
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From the total cohort of 41 patients who under-
went an allo-RIST and were vaccinated, pre- and post-
vaccination sera were available from 26 patients. The
patient group consisted of 15 men (58%) and 11
women. Mean age at vaccination was 56.5 years. Base-
line characteristics of these patients, the donors, and
the transplantation are given in Table 2. Of the total
15 patients that could not be included in this analysis,
baseline characteristics could be traced for 9 patients.
Of 6 patients no further details are known.
The vaccination schedule was designed to start at 1
year posttransplantation, provided the immunosuppres-
sive therapy had ended at that time. As can be seen from
Table 2, themean timebetween theSCTandstart of the
vaccination in practice was 15 months. The reason for
postponing the vaccinations in individual patients wasTable 2. Baseline Characteristics of Patients Included in This Stud
(Although Receiving an allo-RIST)
Patients: n
Male: n (%)
Age at vaccination in years: median (range)
Underlying disease: n (%) Multiple myel
Non-Hodgkin
Chronic lymp
Acute myelog
Mantle cell lym
Chronic myel
M. Waldenstr
Time from SCT to vaccination in months: median (range)
Vaccination>24 months post SCT: n(%)
Immunosuppressive free period in months: median (range)
Leukocytes (*1029/L): median (range)
Donor chimerism >95% at start vaccination: n (%)
Conditioning regimen: n (%) Flu/Cy
TBI
Flu/TBI
Male donor: n (%)
Age donor in years: median (range)
AB0 compatible: n (%)
CMV status: n (%) Patients CMV
Donors CMV
Compatibel
GVHD prophylaxis: n (%) CSA
MMF
Infection prophylaxis: n (%) cotrimoxazol
valaciclovir
penicillin/cipro
Transplant: median (range) CD 34+ cells
T lymphocyte
SCT indicates stem cell transplantation; Flu, fludarabine; Cy, cyclophosphamide
and donor both CMV positive or CMV negative; CsA, cyclosporine A; MMF, mindeed the ongoing use of immunosuppressive therapy
because of activeGVHD.Nine patients (35%) did actu-
ally start with the vaccination schedule at 12 months
posttransplantation. All patients received NMA SCT
for treatment of a hematologic malignancy. Complete
replacement of the host hematopoietic system with do-
nor cells (full donor chimerism) had occurred in 92% of
all patients at start of vaccination.
During the follow-up of the study, several infec-
tious complications occurred in the patient group. Fur-
thermore, in 20 patients (77%) GVHDwas diagnosed.
In this cohort, no acute GVHD (aGVHD) was diag-
nosed. All cases of GVHD started .100 days post-
transplantation (late onset). According to the Seattle
classification of chronic GVHD (cGVHD), the num-
ber of patients with limited and extended GVHD was
determined. A summary of the complications, causative
organisms, and (additional) treatments for GVHD andy and Patients Not Included in the Study
Included Not Included
26 9
15 (58) 3 (33)
56.5 (44-67) 59.1 (42-67)
oma (MM) 11 (42) 3 (33)
lymphoma (NHL) 5 (19) 2 (22)
hocytic leukemia (CLL) 5 (19) 0
enous leukemia (AML) 3 (12) 3 (33)
phoma 1 (4) 0
ogenous leukemia (CML) 1 (4) 0
o¨m 0 1 (11)
15 (12-36) 14.9 (12-21)
5 (19) 0
3.5 (0-9) 4.7 (0-10)
5.5 (3.2-11.9) 6,1 (2.3-12.4)
24 (92) 9 (100)
15 (58) 3 (33)
7 (27) 3 (33)
4 (15) 3 (33)
11 (42) 5 (56)
56 (33-76) 57.9 (47-67)
23 (89) 7 (78)
positive 13 (50) 4 (44)
positive 14 (54) 6 (67)
18 (69) 5 (56)
26 (100) 9 (100)
21 (81) 9 (100)
26 (100) 9 (100)
26 (100) 9 (100)
floxacin 26 (100) 9 (100)
(*1026/kg) 5.7 (2.7-12.2) 5.0 (4.1-6.3)
s (*1027/kg) 30.1 (0.39-62.1) 35.1 (0.3-72.7)
; TBI, total body irradiation; CMV, cytomegalovirus; compatible, patient
ycophenolate mofetil; GVHD, graft-versus-host disease.
Table 3. Complications during Follow-up
Infection: n(%) HZV 3 (12)
Pneumonia Aspergillus spp. 2 (8)
Legionella spp. 1 (4)
S. aureus 1 (4)
H. influenzae 1 (4)
S. viridans 1 (4)
Upper airway
infection e.c.i.
17 (65)
Sepsis P. aeruginosa 1 (4)
Other 19 (73)
CMV reactivation: n(%) 3 (12)
GVHD: n(%) 20 (77)
limited 4 (15)
extensive 16 (62)
Additional
treatment GVHD: n (%)
Prednisolon 4 (15)
Thalidomide 1 (4)
Relapse: n (%) Multiple myeloma 4 (15)
Non-Hodgkin
lymphoma
1 (4)
Treatment relapse: n (%) DLI 3 (12)
Thalidomide 4 (15)
Rituximab 2 (8)
Lenalidomide 2 (8)
Other 3 (12)
HZV indicates herpes zoster virus; CMV, cytomegalovirus; DLI, donor
lymphocyte infusion; GVHD, graft-versus-host disease.
The use of thalidomide as additional treatment for GVHD or as treat-
ment for relapse of malignancy did not occur in the same patient.
1526 Biol Blood Marrow Transplant 15:1523-1530, 2009A. Meerveld-Eggink et al.relapse of the hematologicmalignancy is given inTable
3. None of the patients received intravenous immuno-
globulins posttransplantation.
One year after allo-RIST, patients started with
a vaccination schedule that involved DTP and protein
conjugated polysaccharide vaccines for S. pneumoniae,
Hib, and N. meningitidis type C (see also Table 1).
The conjugated pneumococcal vaccine Prevnar after
2 doses yielded a significant antibody response in the
majority of patients (Table 4). Postvaccination GMT
rose above the level of 0.35 mg/mL for all vaccine sero-
types except polysaccharide 6B (Figure 1).
Seven patients (27%) achieved this chosen thres-
hold antibody concentration for all 7 vaccine serotypes.
The fraction of patients with pre- and postvaccination
pneumococcal serotype-specific IgG concentrations of
$0.35 mg/mL and $1.0 mg/mL, respectively, are
shown in Figure 2.
Geometric mean anti-Hib IgG antibody titers
significantly increased from 0.29 to 4.30 mg/mL after
vaccination. For TT, geometric mean antibody titers
significantly increased from 0.06 IU/mL prevaccina-
tion to 3.42 IU/mL postvaccination (Figure 1).
Except for pneumococcal polysaccharide serotype
6B, $73% of the patients obtain antibody levelsTable 4. IgG Antibody Response after Conjugate Pneumococcal, H
Hib TT PS 4 PS 6B
Seroconversion (n [%]) 20 (78) 22 (85) 22 (85) 12 (46)
Hib indicates Haemophilus influenzae type b; TT, tetanus toxoid; PS, pneumoco
Seroconversion: $4-fold increase in antibody titer after vaccination.considered to be in the protective range ($0.35 mg/
mL) after 2 doses of pneumococcal conjugate vaccine.
Before vaccination, 31% had serotype-specific IgG
concentrations of $0.35 mg/mL for 3 or more pneu-
mococcal serotypes. After vaccination, this percentage
had risen to 85%. If the threshold of $1.0 mg/mL was
chosen, these percentages were 12% before vaccina-
tion and 62% after vaccination.
For Hib conjugate vaccine, 77% of the patients
reached the threshold of 1.0 mg/mL. Prevaccination,
1 patient (4%) had an Hib antibody titer of $1.0 mg/
mL (Figure 3).
After vaccination with 2 doses of TT, all but 1
patient reached the protective threshold of 0.1 IU/
mL; prior to vaccination, the percentage of patients
with protective antibody titers for tetanus was 35%
(9 patients). These results are given in Figure 4.
For Hib, 6 patients did not reach the chosen thres-
hold antibody concentration of 1.0 mg/mL. This group
of hyporesponders consisted of 4 men and 2 women.
Reasons for transplantation were non-Hodgkin
lymphoma (NHL, n53), multiple myeloma (MM,
n52) and chronic lymphocytic leukemia (CLL, n51).
Five patients were conditioned with a regimen of Flu
and Cy prior to vaccination, 1 patient received TBI.
The time from SCT to vaccination varied between 12
and 34 months, with a mean of 17 months. To gain
more insight into the effect of immunosuppressive ther-
apy on the vaccination response, the time between the
endof the immunosuppressive therapy and the first vac-
cination (the immunosuppressive free period) was cal-
culated. The mean immunosuppressive free period
before start of the vaccination schedule was 4 months.
GVHD was seen in 4 patients. No statistically signifi-
cant relation was found between the response to vacci-
nation and age of the patient, age of the donor, sex of
the donor, conditioning regimen, time from SCT to
vaccination, or immunosuppressive free period. One
patient developed a pneumonia caused by Hib, despite
an otherwise adequate response to Hib vaccination.
This was a female acute myeloid leukemia (AML) pa-
tient, treated with a conditioning regimen of Flu and
TBI who developed GVHD.
For the pneumococcal conjugate vaccine, 7 patients
did not reach the chosen threshold antibody
concentration of 0.35 mg/mL for 3 or more vaccine
serotypes. This group consisted of 4 men and 3 women
with NHL (n54), CLL (n51), MM (n51), and mantle
cell lymphoma (n51). All patients were conditioned
with a Flu/Cy regimen. Mean time from SCT toib, and TT Vaccination
PS 9V PS 14 PS 18C PS 19F PS 23F PS 3
19 (73) 18 (69) 18 (69) 18 (69) 16 (62) 3 (12)
ccal polysaccharide.
Figure 1. (A) Geometric mean titers before and after Hib and
pneumococcal vaccination. Geometric mean titers (in mg/mL) with
95% confidence interval prevaccination (gray columns) and postvaccina-
tion (black columns). (B) Geometric mean titers before and after
tetanus vaccination. Geometric mean titers (in IU/mL) with 95%
confidence interval prevaccination (gray column) and postvaccination
(black column).
Figure 2. (A) Percentage of patients with pneumococcal
serotype-specific IgG concentrations $0.35mg/mL pre- and
postvaccination. Percentage of patients with pneumococcal sero-
type-specific IgG concentrations $0.35mg/mL before (gray columns)
and after (black columns) vaccination. (B). Percentage of patients
with pneumococcal serotype-specific IgG concentrations
$1.0mg/mL pre- and postvaccination. Percentage of patients with
pneumococcal serotype-specific IgG concentrations $1.00mg/mL be-
fore (gray columns) and after (black columns) vaccination.
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of the immunosuppressive therapy and start of the vacci-
nation was 3 months. In 4 patients GVHD occurred. Of
the 7 pneumococcal hyporesponders, 4 patients were
also a hyporesponder for Hib. These 4 patients all were
conditionedwith the Flu/Cy regimen.Of the 17 patients
who developed an upper airway infection during the fol-
low-up, 11 patients were good responders toHib and/or
pneumococcal vaccination. As for theHib hyporespond-
ers, also for pneumococcal polysaccharide conjugate vac-
cination, no statistically significant relation was found
between the outcome of vaccination and age of the pa-
tient, age of the donor, sex of the donor, immunosup-
pressive free period or time from SCT to vaccination.
However, theconditioningregimenusedwasadetermin-
ing factor on the outcome of vaccination (P5.025).
Hyporesponse to Hib or pneumococcal vaccines
thus cannot statistically significantly be attributed to
either disease, age, time from SCT to vaccination, or
immunosuppressive free period. It should be noted,
however, that most of the hyporesponders received
Flu/Cy as conditioning regimen and, of the pneumo-
coccal conjugate vaccine failures, 5 patients had anNHL, so there might be a trend toward a relationship
between disease or conditioning regimen and the re-
sponse to vaccination.DISCUSSION
In the current study, patients who underwent an
NMA SCT were vaccinated with Hib, pneumococcal,
and DTP vaccines in a schedule starting 1 year after
transplantation.
Because of the conditioning regimens used before
SCT, antibody concentrations decline and B cell
Figure 3. Percentage of patients with anti-Hib IgG concentra-
tions$1.0mg/mLpre- and postvaccination. Percentage of patients
with anti-Hib IgG concentrations$1.0 mg/mL before (gray column) and
after (black column) vaccination.
Figure 4. Percentage of patients with antitetanus toxoid IgG
concentrations $0.1 IU/mL pre- and postvaccination. Percent-
age of patients with antitetanus toxoid IgG concentrations $0.1 IU/
mL before (gray column) and after (black column) vaccination.
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impairment of humoral immune function after SCT
and the additional effects of immunosuppressive ther-
apy lead to susceptibility to bacterial and viral infec-
tions that may last several years. To prevent these
(bacterial) infections, vaccination is recommended.
However, the (temporary) B cell function deficiencies
may lead to an impaired response to immunization.
Therefore, timing of vaccination is crucial for allowing
for an adequate antibody response to develop in pa-
tients who are treated by SCT. The use of less inten-
sive (NMA) conditioning regimens has reduced
toxicity of the treatment itself, but immune recovery
after such conditioning regimens is not studied exten-
sively [16-18]. In this study, the vaccination-induced
antibody response to vaccination against S. pneumo-
niae, Hib, and TT is measured at 1 year posttransplan-
tation.
The response rate for Hib in this study was 77%
after 1 vaccination. By comparison, van der Velden
et al. [19] found that 6 months after autologous
SCT, only 56% of the patients respond to anti-Hib af-
ter a first dose of vaccine. In a study with myeloablative
(MA) transplant recipients, 55% of the patients
reached protective anti-Hib antibody titers after the
first vaccination at 3 months posttransplantation [20].
In the group of van der Velden et al. [19], the per-
centage of patients with anti-TT antibody titers of
$0.1 IU/mL rose from 50% to 86% after 2 vaccina-
tions starting at 6 months posttransplantation. In our
allo-RIST group, all but 1 patient received protective
tetanus antibody titers after 2 vaccinations. Parkkali
et al. [21] found that afterMA allogeneic SCT, the per-centage of patients with protective anti-TT antibody
titers of $ 0.1 IU/mL was approximately 95% after 2
doses of vaccine, regardless of the time between the
SCT and the start of the vaccination schedule (6 versus
18 months).
The heptavalent conjugated pneumococcal vac-
cine Prevnar contains pneumococcal polysaccharides
of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Sero-
type 3 is not included in the vaccine. Therefore, it
was to be expected that the patients would not develop
an antibody response against this pneumococcal poly-
saccharide. Pneumococcal serotype 6B is known for its
poor antigenicity and postvaccination antibody titers
against 6B were likewise significantly lower as to other
vaccine serotypes.
Twenty-seven percent of the allo-RIST patients
achieved antibody titers above the threshold of
$0.35 mg/mL for all 7 serotypes of the conjugated
pneumococcal vaccine after 2 doses. Three months
following myeloablative SCT, Molrine et al. [22]
found that 36% of the patients reached a titer of
$0.50 mg/mL for all 7 serotypes after the first dose
of vaccine. After the second dose of vaccine, at 6
months posttransplantation, this percentage was
35%. At 12 months posttransplantation, and after re-
ceiving 3 doses of pneumococcal vaccine, 64% reached
this threshold. In the study of vaccination after auto-
logous transplantation, the response rate to a single
dose of Prevnar was only 6% at 6 months posttrans-
plantation. Pneumococcal antibody titers $0.35 mg/
mL increased from 6% to 39% to 72% after a second
Biol Blood Marrow Transplant 15:1523-1530, 2009 1529Vaccination Response after allo-RISTconjugate pneumococcal vaccine (Prevnar) and
a polysaccharide vaccine (Pneumovax-23) at 8 and
14months posttransplantation, respectively. In the im-
munocompromised allo-RIST population, it was
shown that, except for pneumococcal polysaccharide
serotype 6B, $73% of the patients obtain antibody
levels considered to be in the protective range after 2
doses of pneumococcal conjugate vaccine. The com-
plete vaccination protocol consists of a 3-dose pneu-
mococcal vaccine schedule. Blood samples of these
patients at later time points, however, were not avail-
able. Therefore, it is possible that patients who did
not develop an adequate antibody response after 2
doses of pneumococcal vaccine, will develop protective
antibody titers after the third dose of vaccine.
In approximately 25% of the patients, protective
antibody concentrations were not obtained after a first
dose ofHib and2doses of pneumococcal conjugate vac-
cines. In this group, time from transplantation to vacci-
nation varied between 12 to 34 months. All but 1
patient had underwent the conditioning regimen with
Flu and Cy. The prevalent underlying disease was
NHL. Based on this dataset, it is suggested that
the lymphoproliferative disease and the strong immu-
nosuppressive effect of the Flu that is used in the
conditioning regimen determine the outcome of vacci-
nation. The effect of donor age on postvaccination an-
tibody levels was variable in different studies [2,22,23].
In accordance with Storek et al. [23], in this study,
donor age did not affect postvaccination titers.
Only 35% of the patients started the vaccination
schedule at 12 months posttransplantation. In the
majority of patients, vaccination was postponed be-
cause of the use of immunosuppressive therapy at that
time. In some patients, vaccination was started despite
ongoing immunosuppressive therapy. In these pa-
tients, the response to vaccination was variable, not
completely negative. Two patients received thalido-
mide during vaccination and had good responses to
all given vaccines. One patient received prednisolone
and did not reach protective antibody titers after the
given vaccines.
It can be concluded that a vaccination schedule
starting at 12-17 months after allo-RIST yields anti-
body concentrations above the chosen threshold(s) in
the majority of patients after vaccination with TT
and conjugate pneumococcal andHib vaccines. In com-
parison to autologous transplantation, antibody re-
sponse rates are higher in this patient group treated
with an NMA conditioning regimen after 1 dose of
conjugate Hib and 2 doses of pneumococcal vaccine.
A possible explanation might be that, in allogeneic
SCTs, a fully immunocompetent stem cell donor is
used, whereas in autologous transplantation, the hu-
moral immune status of the transplantmay be impaired
because of the hematologic disease and the pretrans-
plant therapy. Second, in the study of van der Veldenet al. [19], autologous stem cell recipients were vacci-
nated at 6months posttransplantation. Amore relevant
and interesting comparison can be made to MA allo-
transplant patients. The allo-RIST patients in this
study started at $12 months posttransplantation. For
MA allogeneic SCT, it was recently shown that there
was no significant difference in response rate to pneu-
mococcal vaccination when starting at 3 or 9 months
posttransplantation, respectively [24]. Further studies
will have to show whether earlier start of the vaccina-
tion schedule induces equally sufficient antibody
responses in the allo-RIST patients, as well as in the in-
creasing number of allo-RIST transplanted with
matched unrelated donor (MUDs).
In summary, vaccination of patients at a median
range of 15 months after NMA SCT leads to signifi-
cant rise in concentrations of pneumococcal, Hib,
and TT antibodies in the majority of patients.ACKNOWLEDGMENTS
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